The TRIUMPH trial program includes over 2,000 participants and is expected to complete in 2026
The PVDF membrane that contained the protein was blocked with 1% (w/v) skim milk in Tris-buffered saline with Tween-20 (TBST) and then incubated overnight with primary antibodies against NF-B (1:500), Akt (1:500), p-Akt (1:1000) (Abcam, UK), P-p65 (1:1000), P38 (1:1000), and p-P38 (1:800) (Cell Signaling, MA, USA) at 4C
Although it is currently not clear if tamoxifen is effective in targeting other types of drug resistant cells that over-express P-gp, based on our current understanding of the mechanism of collateral sensitivity of P-gp-overexpressing cells, we speculate that tamoxifen alone or in combination with rotenone could reduce the rise of drug resistant tumor cells
Empty dots indicate cells with no response
Learn more about who we are on our About Us page